Magnesium Administration in Chronic Kidney Disease
- PMID: 36771254
- PMCID: PMC9920010
- DOI: 10.3390/nu15030547
Magnesium Administration in Chronic Kidney Disease
Abstract
Awareness of the clinical relevance of magnesium in medicine has increased over the last years, especially for people with chronic kidney disease (CKD), due to magnesium's role in vascular calcification and mineral metabolism. The inverse association between serum magnesium and clinically relevant, adverse outcomes is well-established in people with CKD. Subsequent intervention studies have focused on the effect of magnesium administration, mainly in relation to cardiovascular diseases, mineral bone metabolism, and other metabolic parameters. The most commonly used routes of magnesium administration are orally and by increasing dialysate magnesium. Several oral magnesium formulations are available and the daily dosage of elemental magnesium varies highly between studies, causing considerable heterogeneity. Although data are still limited, several clinical studies demonstrated that magnesium administration could improve parameters of vascular function and calcification and mineral metabolism in people with CKD. Current clinical research has shown that magnesium administration in people with CKD is safe, without concerns for severe hypermagnesemia or negative interference with bone metabolism. It should be noted that there are several ongoing magnesium intervention studies that will contribute to the increasing knowledge on the potential of magnesium administration in people with CKD.
Keywords: cardiovascular disease; chronic kidney disease; magnesium; magnesium administration; magnesium supplementation.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Reversal Of Arterial Disease by modulating Magnesium and Phosphate (ROADMAP-study): rationale and design of a randomized controlled trial assessing the effects of magnesium citrate supplementation and phosphate-binding therapy on arterial stiffness in moderate chronic kidney disease.Trials. 2022 Sep 12;23(1):769. doi: 10.1186/s13063-022-06562-9. Trials. 2022. PMID: 36096824 Free PMC article. Clinical Trial.
-
Magnesium and cardiovascular complications of chronic kidney disease.Nat Rev Nephrol. 2015 Jul;11(7):432-42. doi: 10.1038/nrneph.2015.74. Epub 2015 May 12. Nat Rev Nephrol. 2015. PMID: 25963594 Review.
-
Bone and vascular effects of magnesium supplements in CKD patients (the MagicalBone Pilot Study).Nefrologia (Engl Ed). 2024 Sep-Oct;44(5):721-730. doi: 10.1016/j.nefroe.2024.11.001. Nefrologia (Engl Ed). 2024. PMID: 39547778 Clinical Trial.
-
The effect of magnesium supplementation on vascular calcification in chronic kidney disease-a randomised clinical trial (MAGiCAL-CKD): essential study design and rationale.BMJ Open. 2017 Jun 23;7(6):e016795. doi: 10.1136/bmjopen-2017-016795. BMJ Open. 2017. PMID: 28645983 Free PMC article. Clinical Trial.
-
Magnesium and Vascular Calcification in Chronic Kidney Disease: Current Insights.Int J Mol Sci. 2024 Jan 18;25(2):1155. doi: 10.3390/ijms25021155. Int J Mol Sci. 2024. PMID: 38256228 Free PMC article. Review.
Cited by
-
Impact of -20 C° cryopreservation on serum factors from schistosomiasis patients at different storage durations: insights into serum bio-banking.J Parasit Dis. 2025 Mar;49(1):162-172. doi: 10.1007/s12639-024-01734-7. Epub 2024 Oct 1. J Parasit Dis. 2025. PMID: 39975625
-
SGLT2 inhibitors increase low serum magnesium levels in patients with chronic kidney disease immediately after treatment.Clin Exp Nephrol. 2025 Apr;29(4):452-459. doi: 10.1007/s10157-024-02590-8. Epub 2024 Nov 16. Clin Exp Nephrol. 2025. PMID: 39549108
-
Fatal Hypermagnesemia in Patients Taking Magnesium Hydroxide.Electrolyte Blood Press. 2023 Dec;21(2):66-71. doi: 10.5049/EBP.2023.21.2.66. Epub 2023 Dec 18. Electrolyte Blood Press. 2023. PMID: 38152602 Free PMC article.
-
Clinical Guideline for Detection and Management of Magnesium Deficiency in Ambulatory Care.Nutrients. 2025 Feb 28;17(5):887. doi: 10.3390/nu17050887. Nutrients. 2025. PMID: 40077757 Free PMC article.
-
Oxalate Homeostasis in Non-Stone-Forming Chronic Kidney Disease: A Review of Key Findings and Perspectives.Biomedicines. 2023 Jun 7;11(6):1654. doi: 10.3390/biomedicines11061654. Biomedicines. 2023. PMID: 37371749 Free PMC article. Review.
References
-
- Graham L.A., Caesar J.J., Burgen A.S. Gastrointestinal absorption and excretion of Mg 28 in man. Metabolism. 1960;9:646–659. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical